The obesity drug market has expanded rapidly over the past few years, but the next phase of growth will extend well beyond GLP-1s.
In this Scrip-led webinar, our expert journalists examine the evolving obesity landscape, from emerging mechanisms of action and pipeline momentum to market forecasts, deal activity and untapped commercial opportunity. Drawing on intelligence from Evaluate Pharma and Biomedtracker, this session provides essential context for commercial, BD and portfolio decision‑makers navigating what comes next.
Aakash Babu
Managing Editor
View profile
Managing Editor
Pink Sheet, Scrip
Aakash Babu has covered the pharmaceutical sector since 2018, starting his career at Reuters, where he specialised in tackling company news. Just before joining the Citeline team, he worked as a healthcare analyst at the Economist Group, focusing on disease trends, drug development, regulatory changes and pharmaceutical pricing. He has a master’s in economics and a post-graduate specialisation in business journalism from Asian College of Journalism-Bloomberg. He was a key member of the team that covered the initial breakthroughs in COVID-19 vaccine research during his time at Reuters. He also has experience in forecasting regulatory trends, drug approvals and pharmaceutical sales. Outside of work he enjoys traveling, writing and watching football.
Joseph Haas
Senior Writer, US
View profile
Senior Writer, US
Scrip
Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.
Andrew McConaghie
Senior Writer, UK
View profile
Senior Writer, UK
Scrip
Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.
Xu Hu
Senior Reporter, China
View profile
Senior Reporter, China
Pink Sheet, Scrip
Xu is passionate about understanding information and knowledge related to biopharma industry. She is bilingual in Mandarin and English. Prior to this, Xu worked as a medical writer and wrote publications based on data from clinical trials for a wide range of therapeutic areas for global pharmaceutical companies. She holds a Master degree in Medical Pharmaceutical Science from University of Groningen and a PhD degree in Biomedical Science from Vrije Universiteit Amsterdam in the Netherlands.
